Workflow
存款类产品(协定性存款
icon
Search documents
泽璟制药: 中国国际金融股份有限公司关于苏州泽璟生物制药股份有限公司使用部分暂时闲置募集资金进行现金管理事项的核查意见
Zheng Quan Zhi Xing· 2025-05-16 12:24
Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns while ensuring the safety of the raised funds and the implementation of investment projects [1][2][6]. Fundraising Basic Situation - The company was approved to publicly issue 60,000,000 A shares at a price of RMB 33.76 per share, raising a total of RMB 2,025,600,000, with a net amount of RMB 1,908,220,754.68 after deducting related fees [1]. - Additionally, the company was authorized to issue shares to specific targets, raising RMB 1,199,999,955.00, with a net amount of RMB 1,181,933,181.59 after deducting issuance costs [2]. Cash Management Plan - The company plans to use up to RMB 4 billion from the idle funds raised from the initial public offering and up to RMB 8.5 billion from the funds raised from the specific target issuance for cash management [3][4]. - The investment will focus on low-risk, high-liquidity financial products, including but not limited to structured deposits and time deposits, with a maximum investment period of one year [3][4]. Decision Validity and Disclosure - The decision to use idle funds for cash management is valid for 12 months from June 15, 2025, and the company will comply with information disclosure obligations as per regulatory requirements [4][5]. - The income generated from cash management will be prioritized for supplementing investment project funding and daily operational liquidity [4]. Impact on Daily Operations - The cash management plan will not affect the normal operation of the company's investment projects or its main business activities, while also potentially enhancing overall performance and shareholder returns [4][5]. Risk Control Measures - The company has established a risk control framework for cash management, including selecting quality banks and monitoring investment performance to mitigate potential risks [5][6]. - The company will ensure compliance with relevant regulations and maintain a separation of decision-making, execution, and supervision functions in cash management activities [5][6]. Review Procedures - The board of directors approved the cash management plan, which does not require shareholder meeting approval, ensuring adherence to necessary procedures [6][7].
泽璟制药: 泽璟制药关于使用部分暂时闲置募集资金进行现金管理的公告
Zheng Quan Zhi Xing· 2025-05-16 12:15
Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance fund efficiency and generate additional returns while ensuring the safety and proper use of the funds [2][4][8] Fundraising Overview - The company was approved to publicly issue 60 million A-shares at a price of RMB 33.76 per share, raising a total of RMB 2,025,000,000, with a net amount of RMB 1,908,220,754.68 after deducting issuance costs [3] - In April 2023, the company issued 24,489,795 A-shares at RMB 49.00 per share, raising RMB 1,199,999,955, with a net amount of RMB 1,181,933,181.59 after costs [3] Cash Management Plan - The company intends to use up to RMB 4 billion from the idle funds raised from the initial public offering and up to RMB 8.5 billion from the funds raised through a private placement for cash management [2][5] - The cash management will involve purchasing low-risk, liquid principal-protected financial products or deposit products, ensuring that these funds are not used for pledging or securities investments [4][5] Investment Objectives - The primary goal is to improve the efficiency of fund usage and generate additional income without affecting the implementation of investment projects or the safety of the raised funds [4][6] Decision Validity and Management - The decision is valid for 12 months starting from June 15, 2025, and funds can be rolled over within the specified limits [5] - The company’s financial department is responsible for organizing and implementing the cash management activities [5][6] Impact on Daily Operations - The cash management plan will not affect the normal operation of the company’s main business or the regular turnover of funds [6] - The investment returns will be prioritized for supplementing project funding shortfalls and supporting daily operational liquidity [5][6] Regulatory Compliance - The company will adhere to relevant regulations and timely disclose information as required by the China Securities Regulatory Commission and the Shanghai Stock Exchange [5][8] - The sponsor institution has confirmed that the cash management plan complies with regulatory requirements and does not alter the intended use of the raised funds [8]